TYDAL-TIMI 78 is a Phase 2B dose-ranging study of MAR001 in adults with elevated triglycerides and remnant cholesterol.
TYDAL Principal Investigators Drs. Michelle O’Donoghue and Nicholas Marston discuss the trial.
An Academic Research Organization of Brigham & Women's Hospital and An Affiliate of Harvard Medical School